Early Launch Metrics for TG Therapeutics' Briumvi in RMS Trail Those of Novartis' In-Class Competitor Kesimpta, According to Spherix Global Insights

/PRNewswire/ -- With the U.S. commercial launch of TG Therapeutics' Briumvi (ublituximab-xiiy) on January 26th, 2023 for the treatment of relapsing multiple...

Related Keywords

Gemma Mcfadden ,Scott Upham ,Genentech ,Corporate Communications ,Dynamix ,Spherix Network ,Novartis ,Global Insights ,Spherix Global Insights ,Senior Insights Director ,Spherix Global Insight ,